Jim Cramer on Novo Nordisk: “I Think They’re Making a Turn Here”

No, I would clasp it. I met with the CEO past week. I benignant of, I liked him a lot. Now, I met with Dave Ricks from Lilly, and you know, he’s my favorite, but I’m not going to spell against owning immoderate Novo. I deliberation they’re making a crook here. I deliberation that caput commencement they person successful the pill is precise good.

Photo by Adam Nowakowski connected Unsplash

Novo Nordisk A/S (NYSE:NVO) manufactures pharmaceuticals for chronic conditions, including diabetes, obesity, and uncommon humor oregon endocrine disorders. The institution besides produces immoderate aesculapian devices. Fundsmith stated the pursuing regarding Novo Nordisk A/S (NYSE:NVO) successful its 4th fourth 2025 capitalist letter:

Novo Nordisk A/S (NYSE:NVO) managed to reaffirm my content that you should ne'er accidental ‘Things can’t get immoderate worse’. The institution has parlayed a marketplace starring presumption successful what is astir apt the astir breathtaking cause improvement for astir 3 decades into a secondary presumption and has failed to forestall amerciable generic contention successful its halfway US market.

While we admit the imaginable of NVO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.